Initiation of PF614 Phase 3 Enrollment Marks a Major Late-Stage Milestone as Ensysce Advances Its Next-Generation Opioid Toward Potential Commercialization: Ensysce Biosciences announced a significant ...

By Brad Sorensen, CFA NASDAQ: ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ: ENSC) is a clinical stage company that continues to position itself as one of the more differentiated ...

Ensysce Biosciences (NASDAQ:ENSC) stock is in the news today as retail traders take interest in the company with plenty of chatter on social media. Image of a penny held between two fingers with a ...

Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registered direct offering and concurrent private placement. Post-Labor Day Trading ...

The average one-year price target for Ensysce Biosciences (NasdaqCM:ENSC) has been revised to $16.78 / share. This is a decrease of 34.79% from the prior estimate of $25.73 dated April 25, 2026. The ...

Fintel reports that on September 25, 2023, HC Wainwright & Co. maintained coverage of Ensysce Biosciences (NASDAQ:ENSC) with a Buy recommendation. As of August 31, 2023, the average one-year price ...

Short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) increased during the last reporting period, rising from 144.54K to 344.43K. This put 14.69% of the company's publicly available shares short.

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...